Related Experiment Video
Updated: Apr 21, 2026
04:14
Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution
Published on: April 16, 2019
13.0K
Liraglutide-induced acute pancreatitis.
The Journal of the Association of Physicians of India
|October 21, 2014
Summary
A 51-year-old obese woman developed acute pancreatitis after taking Liraglutide (a GLP-1 analogue) for diabetes and weight loss. Symptoms resolved after discontinuing the medication, indicating a potential link.
Area of Science:
- Endocrinology
- Gastroenterology
- Pharmacology
Background:
- Type 2 Diabetes Mellitus (T2DM) management often involves multiple agents.
- Liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, is used for glycemic control and weight reduction in T2DM.
- Patients with T2DM may have underlying risk factors for pancreatic disease.
Observation:
- A 51-year-old obese female with a 13-year history of T2DM was initiated on Liraglutide.
- Eight weeks post-initiation, she presented with severe abdominal pain, nausea, and vomiting.
- Investigations including biochemical tests and CT scan confirmed acute pancreatitis.
Findings:
- Liraglutide was identified as a potential causative agent for acute pancreatitis in this patient.
- Discontinuation of Liraglutide led to the resolution of pancreatitis symptoms.
- Pancreatic enzyme levels normalized upon follow-up after medication cessation.
Implications:
- This case highlights a potential adverse effect of Liraglutide, specifically acute pancreatitis.
- Clinicians should consider pancreatitis in patients presenting with relevant symptoms while on GLP-1 analogues.
- Further research may be warranted to establish the causal relationship and incidence of pancreatitis with GLP-1 receptor agonists.
Related Concept Videos
01:25Acute Pancreatitis I: Introduction
17
Acute pancreatitis is the sudden inflammation of the pancreas caused by the early activation of digestive enzymes, leading to the autodigestion of pancreatic tissue. This results in local inflammation and, in severe cases, systemic complications.EtiologyUnderstanding the underlying causes is crucial, as identifying the etiology guides treatment and anticipates complications. Acute pancreatitis can be triggered by various factors, typically grouped into the following clinical categories.Biliary...
17
01:27Acute Pancreatitis I: Introduction
1.4K
Pancreatitis is inflammation of the pancreas, an organ located behind the stomach. It can be either acute or chronic.
Acute pancreatitis is characterized by rapid inflammation of the pancreas, often caused by factors like gallstone blockage or excessive alcohol consumption. Chronic pancreatitis, on the other hand, is a slow, progressive inflammation that may result from long-term alcohol abuse, obstructions in the pancreatic duct, or genetic factors.
The causes of acute pancreatitis include:
Acute pancreatitis is characterized by rapid inflammation of the pancreas, often caused by factors like gallstone blockage or excessive alcohol consumption. Chronic pancreatitis, on the other hand, is a slow, progressive inflammation that may result from long-term alcohol abuse, obstructions in the pancreatic duct, or genetic factors.
The causes of acute pancreatitis include:
1.4K
01:30Acute Pancreatitis II: Clinical Manifestations and Management
1.1K
Acute pancreatitis presents a complex medical emergency characterized by rapid onset inflammation of the pancreas, demanding timely diagnosis and management to prevent complications. The condition primarily manifests through severe upper abdominal pain that often radiates to the back. This pain intensifies following the consumption of fatty foods. Accompanying symptoms such as nausea, vomiting, abdominal distention, fever, dyspnea, cyanosis, and jaundice can vary in intensity but significantly...
1.1K
01:24Glucagon-like Receptor Agonists
1.3K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.3K
01:21Acute Pancreatitis II: Pathophysiology
25
The pathophysiology of acute pancreatitis centers on injury to pancreatic acinar cells, which initiates a cascade of harmful intracellular events.This injury leads to premature activation of trypsinogen to trypsin in the pancreas. Trypsin then activates other digestive enzymes, such as chymotrypsin, elastase, and phospholipase A2, which begin breaking down pancreatic tissue. The resulting autodigestion causes local inflammation, tissue swelling, hemorrhage, and fat necrosis.Injured acinar cells...
25
01:25Chronic Pancreatitis I: Introduction
21
Chronic pancreatitis is a long-standing, relapsing inflammation of the pancreas, characterized by irreversible damage to the gland. It results in progressive destruction of the pancreatic parenchyma, fibrosis, and eventual loss of both exocrine and endocrine function. The disease may evolve gradually after multiple episodes of acute pancreatitis or develop independently.EtiologyChronic pancreatitis can arise from a variety of causes:Alcohol use is the leading cause, accounting for 70–80%...
21